A method is provided for improving the technological and nutritional properties of gluten-free food matrices based on a fermentation protocol using selected lactic bacteria as starters. The bacteria used are Lactobacillus plantarum strain DSM 33412 and Lactobacillus brevis strain DSM 33413. The method is useful in the processing of gluten-free flowing food material.

The present invention relates to two new strains of lactic acid bacteria, Lactobacillus brevis DSM 33325 and Lactobacillus plantarum DSM 33326, to a new food composition, and to the process for the preparation thereof.

The present disclosure relates to a method for producing fermented green coffee beans and fermented green coffee beans produced thereby, the method including: (A) a step of freezing green coffee beans at −10 to −25° C.; (B) a step of immersing the frozen green coffee beans in water for 3 to 10 hours; (C) a step of taking out the green coffee beans immersed in the water, removing the water and leaving the beans to stand for 5 to 15 hours while supplying air at 20 to 30° C.; (D) a step of sterilizing the green coffee beans and then inoculating the same with a strain to anaerobically ferment the same; and (E) a step of sterilizing and then drying the anaerobically fermented green coffee beans. When the fermented green coffee beans are roasted into coffee beans, aroma and taste may be improved and odor may be removed.

The present invention relates to a gene expression cassette including a strong promoter derived from lactic acid bacteria, and a gene expression vector including the same. According to the present invention, a large amount of a human protein, the physiological activity of which has been verified, may be stably produced with high efficiency by introducing a useful foreign gene into an expression vector and transforming probiotics with the expression vector. Through the production of this protein, it is possible to provide a basis for developing functional probiotics and making products using them.

The present invention relates to the use of a novel Lactobacillus brevis ProGA28 strain, deposited in the German Collection for Microorganisms and Cell Cultures (DSMZ) under the accession number DSM 33167 on May 28, 2019. The metabolites of Lactobacillus brevis ProGA28 have the ability to improve sleep quality, can effectively reduce the time of rapid eye movement in the sleep phase, can reduce time to fall asleep, can increase total sleep time, and can increase the ratio of low waves during sleep so that sleep disorders and related complications, such as anxiety and immune system diseases, are treated.

The present invention relates to bacteria and metabolites thereof that are capable of binding to vaginal cells and producing hydrogen peroxide, their use in probiotic compositions and food products and methods for their selection. The invention also relates to the use of said bacteria, metabolites and probiotic compositions for the prevention and/or treatment of urogenital disorders.

A preparation comprising probiotic strains belonging to the genera Bacillus sp., Lactobacillus sp., optionally Pediococcus sp. as viable cells or cytoplasmic extract thereof, and proteases, wherein the strains can degrade peptide sequences of gliadins. The preparation can be used to produce gluten-free foods from gluten-containing cereals or to treat gluten-related disorders.

The present disclosure relates to a new probiotic strain of Lactobacillus brevis, isolated from pulque and exhibiting anti-cancer properties, as well as to compositions which contain said strain.

Provided is a lactic acid bacteria growth promoter which has a growth promotion effect on lactic acid bacteria. The lactic acid bacteria growth promoter includes at least one peptide selected from the group consisting of: a first peptide having a total number of residues of not more than 9 and comprising a hydrophobic amino acid residue at the C-terminus; and a second peptide having a total number of residues of not more than 9. The ratio of the total number of hydrophobic amino acid residues and proline residues to the total number of residues is not less than 2/3.

Provided is Lactobacillus brevis SPC-SNU 70-2 (KCTC 12777BP) which is novel natural Korean lactic acid bacteria isolated from traditional Korean nuruk.